Biomarkører ved diagnostik af Alzheimers sygdom i tidlig fase

Abstract

Alzheimer's disease is responsible for 40-50% of dementia cases. Future treatment may include disease-modifying compounds unlikely to be efficient if administered late in the course, thus necessitating early diagnosis. Furthermore, revised diagnostic research criteria that include biomarkers of pathological accumulation of cortical beta-amyloid (decreased beta-amyloid in cerebrospinal fluid and amyloid imaging) and neurodegeneration (structural MRI and 18F-FDG-PET), have been published. Future research is needed to determine specific evidence-based application of these biomarkers in the clinic as well as discovery of novel biomarkers.

Bidragets oversatte titelBiomarkers for early diagnosis of Alzheimer's disease
OriginalsprogDansk
ArtikelnummerV12140684
TidsskriftUgeskrift for Laeger
Vol/bind177
Udgave nummer24
ISSN0041-5782
StatusUdgivet - 8 jun. 2015

Fingeraftryk

Dyk ned i forskningsemnerne om 'Biomarkører ved diagnostik af Alzheimers sygdom i tidlig fase'. Sammen danner de et unikt fingeraftryk.

Citationsformater